The stock is still up more than 20% over the past year but Valeant shares are down more than 30% from their recent peak.

Investors are betting Valeant is going to lose its position in the world’s largest generic drugmaker.

The stock was up almost 17% last year before Valeant was hit with a recall of about 4 million capsules, and the stock is up more recently than most drugs on the market.

In the past two years, Valeant has lost almost $8 billion on its stock market investments.

But Valeant also has had a very difficult year as it tries to keep its stock price up.

Analysts believe Valeant may be heading for another big loss.

Here are a few things you should know about Valeant and its stock.1.

The company is now worth $4.4 billion.2.

The average investor owns more than $1.2 billion of Valean stock.3.

Valeant stock is down more in 2017 than in 2016.4.

Valeants stock is trading at less than $6 a share.5.

The S&P 500 has fallen by more than 2% this year compared to last year.6.

The U.S. Treasury has raised Valeant’s credit rating by 1 notch.7.

The FDA is considering a ban on Valeant.8.

Valea has been accused of fraud.

It says its stock is safe and sound.9.

Valean said it is losing money on its drug business.10.

It is trying to sell off some of its assets and is expected to raise about $600 million.